Clinical Trial Update: A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ABT-126 for cognitive deficits in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ABT-126

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED